Table 3.
Comparison of clinical variables between subjects with/without complete remission (CR) by mean difference and relative risk (RR)
| Variables | CR (n = 63) | without CR (n = 66) | ||
|---|---|---|---|---|
| |
Mean ± SD |
Mean ± SD |
Mean difference (95% CI) |
P value |
| Latency to CBZ treatment (yrs) |
11.86 ± 8.07 |
9.70 ± 6.96 |
2.16 (−0.47, 4.78) |
0.106 |
| Period after CBZ treatment (yrs) |
9.49 ± 5.04 |
11.31 ± 5.23 |
−1.82 (−3.61, −0.03) |
0.046 |
| Episode before treatment |
2.57 ± 2.13 |
3.32 ± 2.23 |
−0.75 (−1.51, 0.01) |
0.054 |
| Episode after treatment |
0 |
2.65 ± 1.86 |
−2.65 (−3.11, −2.19) |
<0.001 |
| Drug dose (mg) |
539.68 ± 187.98 |
601.52 ± 231.05 |
−61.83 (−135.42, 11.75) |
0.099 |
| Drug level (μg/mL) |
7.22 ± 1.94 |
8.38 ± 8.03 |
−1.15 (−3.26, 0.95) |
0.280 |
| Age (yrs) |
46.99 ± 11.17 |
44.55 ± 10.58 |
2.44 (−1.35, 6.23) |
0.205 |
| |
N (%) |
N (%) |
RR (95% CI) |
P value |
| Gender (female) |
35 (55.6) |
49 (74.2) |
0.75 (0.58, 0.97) |
0.026 |
| Tobacco use |
9 (14.5) |
15 (22.7) |
1.11 (0.94, 1.31) |
0.234 |
| Alcohol use n |
5 (8.1) |
5 (7.6) |
1.00 (0.90, 1.10) |
0918 |
| Combined use of antipsychotics |
36 (57.1) |
52 (78.8) |
2.02 (1.17, 3.49) |
0.008 |
| Combined use of BZD n |
45 (71.4) |
51 (77.3) |
1.26 (0.70, 2.27) |
0.447 |
| Combined use of lithium |
24 (38.1) |
26 (39.4) |
1.02 (0.78, 1.34) |
0.880 |
| Combined use of valproic acid |
10 (15.9) |
6 (9.1) |
0.93 (0.81, 1.06) |
0.243 |
| Combined use of antidepressant | 6 (9.5) | 8 (12.1) | 1.03 (0.91, 1.16) | 0.635 |
CBZ carbamazepine, SD standard deviation, CI confidence interval, BZD benzodiazepine.